
AMRI Licenses CRISPR from the Broad Institute
AMRI entered into a non-exclusive license agreement with the Broad Institute for the use of CRISPR-Cas9 gene-editing technology.
On August 23, 2016, AMRI announced that it entered into a non-exclusive commercial license agreement with the Broad Institute for the use of CRISPR-Cas9 [Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated] gene-editing technology. Under the terms of the commercial license use, AMRI gained access to intellectual property related to CRISPR-Cas9. The financial terms of the agreement were not disclosed. In a press announcement, AMRI says it plans to use the technology for a number of services the company offers including protein production, cell line and assay development, high content screening and analysis, and target validation and assessment.
Intellectual property rights surrounding CRISPR-Cas9 technology has made
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.